Cargando…
Development of the novel ACLY inhibitor 326E as a promising treatment for hypercholesterolemia
Hepatic cholesterol accumulation is an important contributor to hypercholesterolemia, which results in atherosclerosis and cardiovascular disease (CVD). ATP-citrate lyase (ACLY) is a key lipogenic enzyme that converts cytosolic citrate derived from tricarboxylic acid cycle (TCA cycle) to acetyl-CoA...
Autores principales: | Xie, Zhifu, Zhang, Mei, Song, Qian, Cheng, Long, Zhang, Xinwen, Song, Gaolei, Sun, Xinyu, Gu, Min, Zhou, Chendong, Zhang, Yangming, Zhu, Kexin, Yin, Jianpeng, Chen, Xiaoyan, Li, Jingya, Nan, Fajun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979192/ https://www.ncbi.nlm.nih.gov/pubmed/36873173 http://dx.doi.org/10.1016/j.apsb.2022.06.011 |
Ejemplares similares
-
MiR-326: Promising Biomarker for Cancer
por: Pan, Yao-Jie, et al.
Publicado: (2019) -
The promising novel therapies for familial hypercholesterolemia
por: Chen, Ruoyu, et al.
Publicado: (2022) -
The triterpenoid sapogenin (2α-OH-Protopanoxadiol) ameliorates metabolic syndrome via the intestinal FXR/GLP-1 axis through gut microbiota remodelling
por: Xie, Zhifu, et al.
Publicado: (2020) -
The P326 Gigatracker
por: Scarpa, Marcella
Publicado: (2006) -
A Review of miR-326 and Female Related Diseases
por: Lin, Li-na, et al.
Publicado: (2021)